FDA Snubs MYL, Roche Wins FDA Panel Vote Hands Down, TNXP Falls After-hours

Roche's subcutaneous Rituximab co-formulated with Halozyme Therapeutics' Enhanze Technology has been unanimously recommended for approval by an FDA panel.

from RTT - Biotech http://ift.tt/2oaENYm
via IFTTT